Unknown file type. Enclosure URL IS: - http://64.237.99.107/media/pnc/1/media.1631.pdf
Summary: By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents. While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More
